- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03222024
Cohort Study for Severe Ischaemic Stroke (SIS)
Clinical Features, Management and Outcomes of Severe Ischaemic Stroke in Tertiary Hospitals in China: a Multi-centre Prospective Observational Study
Study Overview
Status
Intervention / Treatment
Detailed Description
Nine tertiary hospitals in Western China are participating in the study. In each participating hospital, stroke patients admitted to the Department of Neurology will be screened by their responsible doctors for eligibility. For patients who are potentially eligible, the doctor will introduce this study in detail with written information to the patient or their legal proxies. After participants (or their proxies) sign the consent form, investigators will collect their baseline data within 24 hours after admission (visit 1). Subsequent visits will be conducted on day 3 of admission or if the patient experiences neurological deterioration between visit 1 and day 3 (visit 2), on day 7 of admission or if neurological deterioration occurs between visit 2 and day 7 (visit 3), and on the day before discharge or on day 30 of admission, whichever is earlier (visit 4). At visit 1 investigators will record demographics, medical history, characteristics of current stroke, and results of the blood tests, brain imaging and other examinations, if applicable. At visit 4, investigators will record interventions and rehabilitation used during hospitalisation. At day 90 and 1 year of stroke onset, a trained investigator (neurologist) blind to all medical information will contact the participant to deliver a structured telephone interview and collect their functional outcomes.
Objectives of this study are: a) to explore causes of clinical worsening in acute ischaemic stroke, and for each type of clinical worsening to dynamically evaluate its clinical course and explore its risk factors; b) to explore the application of conventional stroke therapies in patients with severe ischaemic stroke in China; c) to investigate factors precipitating and predisposing malignant brain oedema following acute ischaemic stroke; and d) to better select patients with malignant brain oedema for individualised treatment strategies.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Sichuan
-
Chengdu, Sichuan, China, 610041
- West China Hospital, Sichuan University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Aged 18 years or over
- Symptoms and signs of clinically definite acute stroke
- Time of stroke onset is known and within 30 days of admission
- CT or MRI brain scanning has reliably excluded both intracranial haemorrhage and structural brain lesions which can mimic stroke (e.g. brain tumour)
Exclusion Criteria:
- Likely to be unavailable for follow-up, e.g. no fixed home address
- Refuse to give consent to participate
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Severe ischaemic stroke
patients with severe stroke on admission
|
This is an observational study for clinical course and outcomes of severe ischaemic stroke; therefore, interventions are prescribed by responsible doctors based on patients' clinical conditions, which is not interfered by current study
|
Malignant ischaemic stroke
patients without severe stroke on admission but developing it in hospital
|
This is an observational study for clinical course and outcomes of severe ischaemic stroke; therefore, interventions are prescribed by responsible doctors based on patients' clinical conditions, which is not interfered by current study
|
Mild to moderate ischaemic stroke
patients without severe stroke from onset to discharge
|
This is an observational study for clinical course and outcomes of severe ischaemic stroke; therefore, interventions are prescribed by responsible doctors based on patients' clinical conditions, which is not interfered by current study
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Functional outcome at 3 months after stroke onset
Time Frame: 3 months after stroke onset
|
Modified Rankin scale score of patients at 3 months after the onset of ischaemic stroke.
|
3 months after stroke onset
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of patients with initially severe ischaemic stroke
Time Frame: 24 hours after admission
|
Initially severe ischaemic stroke is defined as a) severe neurological deficits, assessed by the National Institute of Health Stroke Scale (NIHSS) scored 15 or over, b) loss of consciousness, assessed by the Glasgow Coma Scale (GCS) scored 8 or less, or item 1a of NIHSS scored 1 or over, or c) intubation, mechanical ventilation, or admitted to intensive care unit on admission.
|
24 hours after admission
|
Proportion of patients experiencing clinical worsening following acute ischaemic stroke
Time Frame: 30 days after admission
|
Clinical worsening is defined as a) neurological deterioration with an increase of NIHSS score of 4 or more as compared to baseline NIHSS, b) a decline of consciousness, which leads to a GCS score of 8 or less, or item 1a of NIHSS scored 1 or over, c) need for invasive interventions such as hemicraniectomy, or d) death in hospital.
|
30 days after admission
|
Proportion of patients with malignant brain oedema following acute ischaemic stroke
Time Frame: 30 days after admission
|
Malignant brain oedema is defined as symptoms or signs of clinical worsening associated with imaging evidence of space-occupying brain oedema.
|
30 days after admission
|
Clinical course of stroke severity in patients with initially severe stroke
Time Frame: 30 days after admission
|
Dynamically record scores of National Institute of Health Stroke Scale (NIHSS) from day 0, day 3, day 7 to day 30 after admission.
|
30 days after admission
|
Changes in consicousness level of patients with initially severe stroke from day 0, day 3, day 7 to day 30 after admission.
Time Frame: 30 days after admission
|
Dynamically record scores of Glasgow Coma Scale (GCS)
|
30 days after admission
|
Functional outcome at 1 year after stroke onset
Time Frame: 1 year after stroke onset
|
Modified Rankin scale score of patients at 1 year after the onset of ischaemic stroke.
|
1 year after stroke onset
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Ming Liu, MD, West China Hospital
- Study Director: Shihong Zhang, MD, West China Hospital
- Principal Investigator: Simiao Wu, MD, PhD, West China Hospital
Publications and helpful links
General Publications
- Wu S, Yuan R, Xiong Y, Zhang S, Wu B, Liu M. Clinical features, management and outcomes of severe ischaemic stroke in tertiary hospitals in China: protocol for a prospective multicentre registry-based observational study. BMJ Open. 2018 Oct 28;8(10):e024900. doi: 10.1136/bmjopen-2018-024900.
- Wu S, Yuan R, Wang Y, Wei C, Zhang S, Yang X, Wu B, Liu M. Early Prediction of Malignant Brain Edema After Ischemic Stroke. Stroke. 2018 Dec;49(12):2918-2927. doi: 10.1161/STROKEAHA.118.022001.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2017SZ0007
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Severe Ischaemic Stroke
-
AstraZenecaCompletedAcute Ischaemic Stroke | Transient Ischaemic AttackBelgium, France, Italy, Spain, Sweden, Thailand, Germany, Korea, Republic of, Brazil, Hungary, India, Mexico, Vietnam, China, Taiwan, Hong Kong, Slovakia, Australia, Poland, Saudi Arabia, Ukraine, Canada, Russian Federation, Bulgaria, R... and more
-
AstraZenecaCompletedAcute Ischaemic Stroke | Transient Ischaemic AttackSweden, United States, Australia, Brazil, Bulgaria, France, Italy, Korea, Republic of, Mexico, Peru, Poland, Russian Federation, Spain, Turkey, Vietnam, Germany, Philippines, China, Hungary, Romania, Ukraine, Hong Kong, Argentina, Bel... and more
-
University of LeicesterCompleted
-
Singapore General HospitalSingapore University of Technology and DesignCompletedIschaemic StrokeSingapore
-
BayerCompletedMyocardial Infarction | Unstable Angina | Angina | Ischaemic Heart Disease | Stroke (Including Ischaemic Stroke and Transient Ischaemic Attack)Germany, United Kingdom
-
Institut National de la Santé Et de la Recherche...Fondation de l'AvenirUnknown
-
Boehringer IngelheimCompleted
-
NHS Greater Glasgow and ClydeUniversity of GlasgowCompletedIschaemic StrokeUnited Kingdom
-
NHS Greater Glasgow and ClydeUniversity of Glasgow; Aurum Biosciences LtdUnknown
-
Xiangya Hospital of Central South UniversityRecruiting
Clinical Trials on routine medical care
-
University of Southern CaliforniaCompleted
-
University of PisaUniversity Of Perugia; National Research Council, Institute of Clinical Physiology... and other collaboratorsNot yet recruitingAsthma | Asthma Severe Persistent UncontrolledItaly
-
Children's Hospital of Fudan UniversityWithdrawnAttention Deficit Hyperactivity Disorder
-
Beijing Ditan HospitalCompletedHepatocellular CarcinomaChina
-
Beijing Ditan HospitalXiyuan Hospital of China Academy of Chinese Medical SciencesCompletedHepatocellular CarcinomaChina
-
Beijing Ditan HospitalRecruitingHepatocellular CarcinomaChina
-
Beijing Ditan HospitalActive, not recruiting
-
Hoag Memorial Hospital PresbyterianInstitute for Systems Biology; ArivaleCompletedCognitive Impairment | Alzheimer DiseaseUnited States
-
Yonsei UniversityCompletedPancreaticobiliary CancerKorea, Republic of
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedOcular Hypertension | GlaucomaSpain, Czechia, Sweden, Germany, France, Greece, Belgium, Colombia, Denmark, Italy, Peru, Portugal, Slovakia, United Kingdom